These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23402573)

  • 1. Using common random numbers in health care cost-effectiveness simulation modeling.
    Murphy DR; Klein RW; Smolen LJ; Klein TM; Roberts SD
    Health Serv Res; 2013 Aug; 48(4):1508-25. PubMed ID: 23402573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
    Murphy DR; Smolen LJ; Klein TM; Klein RW
    BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" 1i [type C] FLS.
    Majumdar SR; Lier DA; Hanley DA; Juby AG; Beaupre LA;
    Osteoporos Int; 2017 Jun; 28(6):1965-1977. PubMed ID: 28275838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
    Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
    Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
    Ni W; Jiang Y
    Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted?
    Gajic-Veljanoski O; Bayoumi AM; Tomlinson G; Khan K; Cheung AM
    Osteoporos Int; 2012 Nov; 23(11):2681-92. PubMed ID: 22398856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.
    O'Hanlon CE; Parthan A; Kruse M; Cartier S; Stollenwerk B; Jiang Y; Caloyeras JP; Crittenden DB; Barron R
    Clin Ther; 2017 Jul; 39(7):1276-1290. PubMed ID: 28629610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.
    Mohd-Tahir NA; Thomas P; Mohamed-Said MS; Makmor-Bakry M; Li SC
    Int J Rheum Dis; 2018 Mar; 21(3):647-655. PubMed ID: 29105349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of osteoporosis screening strategies for hip fracture prevention in older Chinese people: a decision tree modeling study in the Mr. OS and Ms. OS cohort in Hong Kong.
    Su Y; Lai FTT; Yip BHK; Leung JCS; Kwok TCY
    Osteoporos Int; 2018 Aug; 29(8):1793-1805. PubMed ID: 29774400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
    Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
    Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effective osteoporosis treatment thresholds in Greece.
    Makras P; Athanasakis K; Boubouchairopoulou N; Rizou S; Anastasilakis AD; Kyriopoulos J; Lyritis GP
    Osteoporos Int; 2015 Jul; 26(7):1949-57. PubMed ID: 25740208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
    Albert SG; Reddy S
    Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.
    Hernandez I; Zhang Y
    J Eval Clin Pract; 2015 Oct; 21(5):840-7. PubMed ID: 26059485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis.
    Hiligsmann M; Ben Sedrine W; Bruyère O; Reginster JY
    Osteoporos Int; 2013 Aug; 24(8):2291-300. PubMed ID: 23371359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women.
    Yoshimura M; Moriwaki K; Noto S; Takiguchi T
    Osteoporos Int; 2017 Feb; 28(2):643-652. PubMed ID: 27743068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for and treatment of osteoporosis: construction and validation of a state-transition microsimulation cost-effectiveness model.
    Si L; Winzenberg TM; Jiang Q; Palmer AJ
    Osteoporos Int; 2015 May; 26(5):1477-89. PubMed ID: 25567776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A health economic simulation model for the clinical management of osteoporosis.
    Jonsson E; Hansson-Hedblom A; Ljunggren Ö; Åkesson K; Spångeus A; Kanis JA; Borgström F
    Osteoporos Int; 2018 Mar; 29(3):545-555. PubMed ID: 29196775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
    Moriwaki K; Fukuda H
    Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.